Unknown

Dataset Information

0

CD106 is a novel mediator of bone marrow mesenchymal stem cells via NF-?B in the bone marrow failure of acquired aplastic anemia.


ABSTRACT:

Background

Acquired aplastic anemia (AA) is characterized by deficiency or dysfunction of the bone marrow (BM) microenvironment. However, little is known about the impairment of BM-derived mesenchymal stem cells (MSCs) in AA patients.

Methods

We used Illumina HiSeqTM 2000 sequencing, quantitative real-time polymerase chain reaction (qRT-PCR), flow cytometry (FCM), and Western blotting to test the expression of CD106 gene (vascular cell adhesion molecule 1 (VCAM1)) and CD106 protein of BM-MSCs. Furthermore, we used hematoxylin and eosin (H&E) and histochemical staining analysis, immunofluorescence, and the formation of capillary-like structures to analyze capillary tube-like formation in vitro; we also used the Matrigel plug assay to test in vivo vasculogenesis, and an assay of colony forming units (CFUs) and colony-forming unit-megakaryocyte (CFU-MK) to detect the support function of MSCs in vitro. The in vivo engraftment of CD34+ cells and MSCs in NOD/SCID mice was tested by FACS and survival assay; the expression of NF-?B was tested by NanoPro analysis and immunofluorescence. NF-?B-regulated CD106 gene (VCAM1) was confirmed by tumor necrosis factor alpha (TNF-?)-stimulated and lipopolysaccharide (LPS)-stimulated MSCs, blockade assay, and immunofluorescence.

Results

Here, we report that BM-MSCs from AA patients exhibited downregulation of the CD06 gene (VCAM1) and low expression of CD106 in vitro. Further analysis revealed that CD106+ MSCs from both AA patients and healthy controls had increased potential for in vitro capillary tube-like formation and in vivo vasculogenesis compared with CD106- MSCs, and the results were similar when healthy MSCs were compared with AA MSCs. CD106+ MSCs from both AA patients and healthy controls more strongly supported in vitro growth and in vivo engraftment of CD34+ cells in NOD/SCID mice than CD106- MSCs, and similar results were obtained when healthy MSCs and AA MSCs were compared. The expression of NF-?B was decreased in AA MSCs, and NF-?B regulated the CD106 gene (VCAM1) which supported hematopoiesis.

Conclusions

These results revealed the effect of CD106 and NF-?B in BM failure of AA.

SUBMITTER: Lu S 

PROVIDER: S-EPMC5540520 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

CD106 is a novel mediator of bone marrow mesenchymal stem cells via NF-κB in the bone marrow failure of acquired aplastic anemia.

Lu Shihong S   Ge Meili M   Zheng Yizhou Y   Li Jianping J   Feng Xiaoming X   Feng Sizhou S   Huang Jinbo J   Feng Ying Y   Yang Donglin D   Shi Jun J   Chen Fang F   Han Zhongchao Z  

Stem cell research & therapy 20170801 1


<h4>Background</h4>Acquired aplastic anemia (AA) is characterized by deficiency or dysfunction of the bone marrow (BM) microenvironment. However, little is known about the impairment of BM-derived mesenchymal stem cells (MSCs) in AA patients.<h4>Methods</h4>We used Illumina HiSeqTM 2000 sequencing, quantitative real-time polymerase chain reaction (qRT-PCR), flow cytometry (FCM), and Western blotting to test the expression of CD106 gene (vascular cell adhesion molecule 1 (VCAM1)) and CD106 protei  ...[more]

Similar Datasets

| S-EPMC5733198 | biostudies-other
| S-EPMC4021843 | biostudies-literature
| S-EPMC6290278 | biostudies-other
| S-EPMC3698520 | biostudies-literature
| S-EPMC6063510 | biostudies-literature
2011-11-19 | E-GEOD-33812 | biostudies-arrayexpress